Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MedImmune LLC
To evaluate the pharmacokinetic characteristics of MEDI-507 given in dose intervals.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Renal allograft recipients receiving their first or second allograft
Age over 18
Maintained on conventional immunosuppression
Completed informed consent document
You may not be if
Known hypersensitivity to MEDI-507
More than two renal allografts
Moribund and unlikely (in the opinion of the investigator) to survive the duration of the trial
Simultaneous use of other investigational agents (this does not include the use of licensed agents for indications not listed in the package insert)
Any of the following clinical settings or diagnoses posttransplant:
pregnancy or nursing mother: Ø Human Immunodeficiency Virus infection Ø hemodialysis or chronic peritoneal dialysis Ø use of a ventilator Ø hyperacute rejection
Having received OKT3, tacrolimus, or antilymphocyte globulin during the current allograft
Less than 10 ml/hr average urine output over 4 hours since the end of surgery
Clareo Health | A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection
